Managing glaucoma in those with co-morbidity: Not as easy as it seems

Ophthalmic Epidemiology

Volumn 19, Issue 2, 2012, Pages 74-82

  Roughead, Elizabeth E ^a   Kalisch, Lisa M ^a   Pratt, Nicole L ^a   Killer, Graeme ^b   Barnard, Amanda ^c   Gilbert, Andrew L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Department of Veterans' Affairs ^*  (Australia)

^c The Australian National University   (Australia)

Author keywords

Co morbidity; Contraindications; Drug disease interaction; Glaucoma; Treatment conflict

Indexed keywords

APRACLONIDINE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CORTICOSTEROID; DIPIVEFRINE; DORZOLAMIDE; EYE DROPS; LATANOPROST; LEVOBUNOLOL; PILOCARPINE; TIMOLOL; TRAVOPROST; VERAPAMIL;

ARTICLE; ASTHMA; AUSTRALIA; BRADYCARDIA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; GLAUCOMA; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; VETERAN;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; COMORBIDITY; DEPRESSIVE DISORDER; DIABETES MELLITUS; FEMALE; GLAUCOMA; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; RESPIRATION DISORDERS; RETROSPECTIVE STUDIES; VETERANS;

EID: 84859082772     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.3109/09286586.2011.638743     Document Type: Article

References (29)

1. Centre for Allied Health Evidence. Final report. Systematic literature review on the detection, diagnosis, management and prevention of glaucoma. Canberra: NHMRC, Department of Health and Ageing; 2009.
2. Canadian Glaucoma Study Group. Canadian glaucoma study: 1. Study design, baseline characteristics and preliminary analyses. Can J Ophthalmol 2006;41:566-75.
3. Gottfredsdottir M, Allingham R, Shields M. Physicians' guide to interactions between glaucoma and systemic medications. J Glaucoma 1997;6:377-383.
4. Valuck R, Perlman J, Anderson C, Wortman G. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: Estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf 2001;10:511-516.
5. Vander Zanden J, Valuck R, Bunch C, Perlman J, Anderson C, Wortman G. Systemic adverse effects of ophthalmic beta blockers. Ann Pharmacotherapy 2001;35:1633-1637.
6. Hallas J. Evidence of depression provoked by cardiovascular medication: Prescription sequence symmetry analysis. Epidemiology 1996;7:478-484.
7. Tsiropoulos I, Andersen M, Hallas J. Adverse events with useof antiepileptic drugs: A prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 2009;18(6):483-491.
8. Caughey G, Roughead E, Pratt N, Shakib S, Vitry A, Gilbert A. Increased risk of hip fracture in the elderly associatedwith prochlorperazine: Is a prescribing cascade contributing?Pharmacoepidemiol Drug Saf 2010;19(9):977-82.
9. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Code Classification index with Defined Daily Doses. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology; 2004. Available from: Http://www. whocc.no/atcddd/. Accessed 2004 Feb 4.
10. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits Canberra: National Capital Printing; 2007. Accessed July 17, 2007 from: Http:// www.pbs.gov.au/html/healthpro/home
11. National Centre for Classification in Health. The international statistical classification of diseases and related health problems,10th revision, Australian Modification (ICD-10-AM).Sydney: Lidcombe, NSW; 2000.
12. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacistsand medical practitioners. Effective 1 January 2008-31January 2008. Commonwealth of Australia; 2008. AccessedJanuary 11, 2008 from: Http://www.pbs.gov.au/html/ healthpro/ publication/archive
13. King M, Purdie D, Roberts M. Matching prescription claims with medication data for nursing home residents: Implications for prescriber feedback, drug utilisation studies and selection of prescription claims database. J Clin Epidemiol 2001;54:202-209.
14. Sloan K, Sales A, Liu C, et al. Construction and characteristics of the RxRisk-V. A VA-Adapted pharmacy-based case-mix instrument. Med Care 2003;41(6):761-774.
15. National Health and Medical Research Council. NHMRC Guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma 2010. Canberra: Australian Government NHMRC; 2010.
16. Australian Medicines Handbook 2009. Adelaide: Australian Medicines Handbook; 2009.
17. Carroll S, Gaskin B, Goldberg I, Danesh-Meyer H. Glaucoma prescribing trends in Australia and New Zealand. Clin Exp Ophthalmol 2006;34:213-218.
18. Calvo-Romero J, Lima-Rodriguez E. Bradycardia associated with ophthalmic beta-blockers. J Postgrad Med 2003;49(2):186.
19. Sharifi M, Koch J, Steele R, Adler D, Pompili V, Sopko J. Third degree AV block due to ophthalmic timolol solution. Int J Cardiol 2001;80:257-259.
20. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. European Glaucoma Society; 2008.
21. Frishman W, Kowalski M, Nagnur S, Warshafsky S, Sica D. Cardiovascular considerations in using topical, oral and intravenous drugs for the treatment of glaucoma and ocular hypertension. Focus on beta-Adrenergic blockade. Heart Disease 2001;3:386-397.
22. Hedner J, Svedmyr N, Lunde H, Mandahl A. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Survey Ophthalmol 1997;41(Suppl. 2): S111-115.
23. Hedner J, Everts B, Strom Moller C. Latanoprost and respiratory function in asthmatic patients. Randomized, double masked, placebo-controlled crossover evaluation. Arch Ophthalmol 1999;117:1305-1309.
24. Arranz Marquez E, Teus Guezala M, Canseco Gonzalez F. Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD) [in Spanish]. Archiv Soc Española Oftalmol 2002;77(10):553-558.
25. Liang Y, Li C, Guzman V, Evinger A, Protzman C, Krauss A, Woodward D. Comparison of prostaglandin F2α, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem 2003;278(29):27267-27277.
26. Houde M, Castilloux A, Tingey D, Assalian A, LeLorier J. Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. Can J Ophthalmol 2003;38:469-475.
27. Goldberg I, Moloney G, McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Med J Aus 2008;189(7):356-357.
28. Australian Institute of Health and Welfare (AIHW). Health care usage and costs. A comparison of veterans and war widows and widowers with the rest of the community. Cat. no. PHE 42. Canberra: AIHW; 2002.
29. Australian Government National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for developers of guidelines. 2009. Accessed April 1, 2011 from: Http://www.nhmrc.gov.au/- files-nhmrc/file/guidelines/evidence-statement-form. Pdf